| Name | 5-methyl-4-oxidopyrazin-4-ium-2-carboxylic acid |
|---|---|
| Synonyms |
5-methyl-2-pyrazinoic-4-oxide
2-Cboxy-5-methylpyrazine 4-oxide 5-Methylpyrazine-2-cboxylic Acid 4-Oxide 5-Methylpyrazine-2-cboxylicAcid4-Oxide> 2-Carboxy-5-methylpyrazine 4-oxide,5-Methylpyrazinecarboxylic acid 4-oxide Acipimox Solution, 100ppm 5-Carboxy-2-methylpyrazine 1-oxide 5-methylpyrazine-2-carboxylic acid 4-oxide 2-carboxy-5-methylpyrazine 4-oxide Acimus K-9321 Olbetam Acipimox (K-9321) 2-Cboxy-5-methylpyrazine 4-oxide, 5-Methylpyrazinecboxylic acid 4-oxide Acipimox Powder Standd Acipimox Solution, 1000ppm Acipimox //BP 4-Oxide-5-Methylpyrazine-2-CboxylicAcid 5-methyl-2-pyrazinecboxylicacid4-oxide Acipimox, 10 mM in DMSO 5-METHYLPYRAZINECBOXYLICACID4-OXIDE 2-methyl-5-pyrazinecarboxylic acid 1-oxide 2-Pyrazinecboxylic acid, 5-methyl-, 4-oxide l^{5},4-pyrazine-3-cboxylic acid MFCD00865757 ACIPIMOX 2-Pyrazinecarboxylic acid, 5-methyl-, 4-oxide 5-Methyl-4-oxidopyrazin-4-ium-2-cboxylic acid 5-methyl-2-pyrazinecboxylicaci4-oxide 6-Methyl-1-oxo-1 5-methyl-4-oxy-pyrazine-2-carboxylic acid Acipimox (5-Methylpyrazinecboxylic acid 4-oxide) Acipimox - Bio-X 5-Methyl-4-oxide-2-pyrazinecboxylicacid Methylpyrazine Oxide AcipiMox-13C2,15N2 5-methyl-4-oxidopyrazin-4-ium-2-cboxylicaci 5-Methylpyrazinecarboxylic acid 4-oxide Acyclovir therapy 5-methyl-4-oxido-2-pyrazin-4-iumcboxylic acid 4-Oxo-5-Methyl-2-Pyrazine-cboxylic Acid 5-Cboxy-2-methylpyrazine 1-oxide 5-Methyl-2-pyrazinecarboxylic acid 4-oxide Olbemox EINECS 256-928-3 5-METHYLPYRANZINECBOXYLIC ACID 4-OXIDE T6N DNJ AO B1 EVQ |
| Description | Acipimox is a niacin derivative used as a hypolipidemic agent.Target: Acipimox is a niacin derivative used as a hypolipidemic agent. It is used in low doses and may have less marked adverse effects, although it is unclear whether the recommended dose is as effective as are standard doses of nicotinic acid. Acipimox inhibits the production of triglycerides by the liver and the secretion of VLDL, which leads indirectly to a modest reduction in LDL and increase in HDL. Long-term administration is associated with reduced mortality, but unwanted effects limit its clinical use. Adverse effects include flushing (associated with Prostaglandin D2), palpitations, and GI disturbances. Flushing can be reduced by taking aspirin 20-30 min before taking Acipimox. High doses can cause disorders of liver function, impair glucose tolerance and precipitate gout. From Wikipedia. |
|---|---|
| Related Catalog | |
| References |
| Density | 1.4±0.1 g/cm3 |
|---|---|
| Boiling Point | 539.0±45.0 °C at 760 mmHg |
| Melting Point | 177-180 °C |
| Molecular Formula | C6H6N2O3 |
| Molecular Weight | 154.123 |
| Flash Point | 279.8±28.7 °C |
| Exact Mass | 154.037842 |
| PSA | 75.65000 |
| LogP | -1.38 |
| Vapour Pressure | 0.0±1.5 mmHg at 25°C |
| Index of Refraction | 1.608 |
| Storage condition | 2-8°C |
CHEMICAL IDENTIFICATION
HEALTH HAZARD DATAACUTE TOXICITY DATA
|
| Symbol |
GHS07 |
|---|---|
| Signal Word | Warning |
| Hazard Statements | H319 |
| Precautionary Statements | P305 + P351 + P338 |
| Personal Protective Equipment | dust mask type N95 (US);Eyeshields;Gloves |
| Hazard Codes | Xi: Irritant; |
| Risk Phrases | R36 |
| Safety Phrases | S26 |
| RIDADR | NONH for all modes of transport |
| RTECS | UQ2453000 |
| HS Code | 2942000000 |
|
~%
51037-30-0 |
| Literature: Carlo Erba S.p.A. Patent: US4002750 A1, 1977 ; |
|
~%
51037-30-0 |
| Literature: Carlo Erba S.p.A. Patent: US4002750 A1, 1977 ; |
|
~%
51037-30-0 |
| Literature: Montedison S.p.A. Patent: US4866178 A1, 1989 ; |
|
~%
51037-30-0 |
| Literature: Ambrogi; Cozzi; Sanjust; et al. European Journal of Medicinal Chemistry, 1980 , vol. 15, # 2 p. 157 - 163 |
|
~%
51037-30-0 |
| Literature: Ambrogi; Cozzi; Sanjust; et al. European Journal of Medicinal Chemistry, 1980 , vol. 15, # 2 p. 157 - 163 |
| Precursor 5 | |
|---|---|
| DownStream 2 | |
| HS Code | 2933990090 |
|---|---|
| Summary | 2933990090. heterocyclic compounds with nitrogen hetero-atom(s) only. VAT:17.0%. Tax rebate rate:13.0%. . MFN tariff:6.5%. General tariff:20.0% |